LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Vesigen Therapeutics Inc.
Headquarters:
Cambridge, MA, United States of America
Website:
https://www.vesigentx.com/
Year Founded:
2019
Status:
Private
BioCentury
|
Oct 19, 2024
Finance
Biotech restructurings show signs of slowing
Temporary respite or reflection of a stabilizing sector?
Read More
BioCentury
|
Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
Read More
BioCentury
|
Apr 12, 2022
Management Tracks
Lowe’s Denton becomes CFO at Pfizer
Plus Werner named CEO at Alltrna, and updates from AptarGroup, MBX, Vesigen and more
Read More
BioCentury
|
Mar 26, 2022
Emerging Company Profile
Affini-T: engineering T cells to target oncogenic drivers in solid tumors
With $175M in the bank, Fred Hutch spinout is adding synthetic biology switches to T cells to increase their tumor infiltration and persistence
Read More
BioCentury
|
Jul 23, 2020
Deals
July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG
Read More
Items per page:
10
1 - 5 of 5